China's first ECMO successfully developed

Domestic first ECMO successfully developed

Domestic first ECMO successfully developed, the first extracorporeal membrane pulmonary oxygenation device in China. Extracorporeal Membrane Pulmonary Oxygenation (ECMO) devices have long relied on imports, and this domestic ECMO device breaks through the monopoly of foreign technology with the successful development of the first domestic ECMO.

The first domestic ECMO successfully developed1

On November 8, the reporter learned from the First Affiliated Hospital of Xi'an Jiaotong University, recently, the First Affiliated Hospital of Xi'an Jiaotong University, Sichuan University National Biomedical Materials Engineering and Technology Research Center, Xi'an Jiaotong University School of Mechanical Sciences, the joint development of the first domestic extracorporeal membrane pulmonary oxygenation device (referred to as ECMO), the first affiliated hospital in Xi'an Jiaotong University, cardiovascular hospital of Xi'an Jiaotong University, Yuan Zuyi, Prof. Yan Yang's team was the first in China to apply it in the clinic and successfully treated two patients with critical cardiovascular diseases.

The successful application of domestic ECMO in the clinic breaks the monopoly of foreign products in this field, realizes a breakthrough in the independent development of domestic major medical devices, and cracks the "neck" problem of cardiovascular patients with critical illnesses, which is a "great power" in the field of healthcare.

This is another major scientific achievement of the First Affiliated Hospital of Xi'an Jiaotong University in the creation of the National Medical Center.

ECMO is a powerful weapon for patients with severe cardiopulmonary failure to fight against death, but its core key technology has been monopolized by foreign countries for a long time, and the price of equipment and consumables is expensive, which is the "neck" problem in the field of health care, and the development of homemade ECMO is imminent.

The cardiovascular team of the First Affiliated Hospital of Xi'an Jiaotong University is one of the earliest units to carry out ECMO clinical work in China, and has been engaged in the clinical application of ECMO and related research for more than 20 years, and is also one of the earliest units in China to research and develop medical devices, such as membrane oxygenators and perfusion tubing.

The successful application of the first domestic ECMO system developed by the team to the clinic is expected to significantly reduce the domestic selling price of ECMO products, promote the popularization of ECMO technology to grass-roots hospitals, and benefit more patients with acute and critical illnesses, which is of great strategic significance and social benefits.

The first ECMO in China was successfully developed2

Recently, the first extracorporeal membrane pulmonary oxygenation device in China was successfully developed and utilized in the clinic. Yuan Zuyi, director of the Cardiovascular Disease Hospital of the First Affiliated Hospital of Xi'an Jiaotong University, a co-developer of the device, said that extracorporeal membrane pulmonary oxygenation equipment (ECMO) has long relied on imports, and that this homegrown ECMO device breaks through the monopoly of foreign technology, and also utilizes new technologies such as magnetic navigation and magnetic control technology.

Basic principle

When ECMO is in operation, blood is drawn from the vein, oxygenated through the membrane lung, and carbon dioxide is discharged, and the oxygenated blood can be returned to the vein (V-V diversion), or returned to the artery (V-A diversion).

V-V diversion:

Mainly used for extracorporeal respiratory support, the venous blood will be partially exchanged before flowing through the lungs, to make up for the insufficiency of the lungs.V-V diversion through the vein will be drawn out of the venous blood through the oxygenator oxygenation and exclusion of carbon dioxide, and then pumped into another vein. Usually the femoral vein is used and the internal jugular vein is pumped in, but bilateral femoral veins may be used depending on the patient's condition.V-V diversion is appropriate in cases of purely impaired lung function without risk of cardiac arrest.V-V diversion only partially replaces lung function because only a portion of the blood is pre-oxygenated and there is double circulation through the tubing. The phenomenon of recirculation means that part of the blood is pumped through the ECMO line into the vein and then sucked back into the ECMO line, repeating the oxygenation.

V-A Diversion:

Used for both extracorporeal respiratory support and cardiac support, the blood pump replaces the pumping function of the heart and maintains circulation.V-A Diversion draws venous blood from the veins, which is pumped into the arteries after being oxygenated by the oxygenator and eliminating carbon dioxide.V-A Diversion is a simultaneous V-A diversion is a connection that simultaneously supports cardiopulmonary function and is suitable for cases of cardiac failure, severe pulmonary failure and the possibility of cardiac arrest.V-A diversion's extracorporeal circulatory line is connected in parallel with the heart and lungs, and the operation process increases the cardiac afterload and reduces the amount of blood flowing through the lungs, which can lead to pulmonary edema and even pink foamy sputum in prolonged operation. In addition, when the heart stops completely, the blood in the heart stagnates in V-A mode, which is prone to thrombosis and leads to irreversible damage.

ECMO mode should be chosen flexibly with reference to the etiology and condition. In general, V-V diversion is a pulmonary alternative mode and V-A diversion is a combined cardiopulmonary alternative mode.

Extracorporeal membrane pulmonary oxygenation is mainly applied to the following:

Patients with cardiac arrest

Patients with acute severe cardiac failure

Patients with acute severe respiratory failure

Other 'diseases' that seriously threaten respiratory and circulatory function

Organ transplantation support, waiting for a Donor

China's first ECMO successfully developed3

Extracorporeal membrane pulmonary oxygenation equipment (hereinafter referred to as ECMO) has been monopolized by foreign countries, is China's cardiovascular patients with critical illnesses rescue and treatment of the "neck" of the problem, and now China's first homegrown ECMO system has been successfully applied to the clinic, realizing a breakthrough in the development of domestic major medical equipment independently, cracking the problem of what is known as the "neck". On November 8, the First Affiliated Hospital of Xi'an Jiaotong University held a media conference on "Domestic ECMO Research and Development Achieves Major Breakthrough for Clinical Use", with Yan Hong, Vice President of Xi'an Jiaotong University, The director of the Shaanxi Provincial Food and Drug Administration, Yao Xiong, President of the First Affiliated Hospital of Xi'an Jiaotong University, Lv Yi, Deputy Secretary Han Ju, President of the Cardiovascular Hospital, Yuan Zuyi, Director of the Cardiovascular Surgery Department, Yan Yang, Xi'an Jiaotong University Mechanical College Professor Zhuang Jian, Xi'an Jinggong Medical Science and Technology Company, Professor Wang Jingyu, and other speakers at the meeting.

ECMO is jointly developed by the First Affiliated Hospital of Xi'an Jiaotong University, the National Biomedical Materials Engineering Technology Research Center of Sichuan University, and the School of Mechanics of Xi'an Jiaotong University. The team of Prof. Yuan Zuyi and Prof. Yan Yang from the School of Cardiovascular Diseases of the First Affiliated Hospital of Xi'an Jiaotong University has taken the lead in applying the first home-made ECMO system to the clinic in China, and successfully treated two patients with critical cardiovascular diseases.

The cardiovascular team of the First Affiliated Hospital of Xi'an Jiaotong University has been engaged in the clinical application of ECMO and related research for more than 20 years, reviewing the road of domestic ECMO research and development can not be separated from the government's help, teamwork, learning and research as a whole. 2017 the team joined forces with the team of academician Zhang Xingdong, director of the National Center for Biomedical Materials Engineering Technology Research at Sichuan University, and director of the team Wang Yunbing, In 2017, the team, together with academician Zhang Xingdong of Sichuan University National Biomedical Materials Engineering Technology Center, director Wang Yunbing's team, professor Zhuang Jian's team of Xi'an Jiaotong University's School of Mechanical Engineering, and Xi'an Jinggong Medical Science and Technology Company, launched the in-depth design and research and development of ECMO equipment with long-lasting anticoagulant coatings for the whole blood-contacting surface, magnetic suspension centrifugal pumps, ultrasonic flow probes, programmed control monitoring systems, and ECMO membrane lungs. The team also conducted large animal experiments on the anticoagulant coating.

The team's successful development of the first set of domestic ECMO system successfully applied to the clinical, is expected to significantly reduce the domestic selling price of ECMO products, to promote the popularization of ECMO technology to the grass-roots hospitals, so that more patients with acute and critical illnesses to benefit from the next step, the First Affiliated Hospital of XI'AN Jiaotong University will continue a series of cardiovascular critical care instrumentation aspects of the research.